Press Enter to search · Esc to close
New real-world data is shifting the GLP-1 conversation from 'does it work' to 'how to use it without getting hurt.' Here's what the latest evidence actually says.
A massive new target-trial emulation hints that semaglutide and tirzepatide may do more than shrink waistlines — they may quietly cut the odds of obesity-driven cancers. Here's what the data actually say.
A phase 3 trial of a glucagon/GLP-1 dual agonist lands alongside a semaglutide biosimilar and new cardiometabolic signals — incretin therapy is outgrowing the obesity box.
A 2026 systematic review reframes the pre-anesthesia question for semaglutide users — less about pausing the drug, more about clearing the stomach and checking it with ultrasound.
Semaglutide reshaped the conversation around obesity. The next round of data — from skeletal muscle to intracranial pressure to oral small molecules — is reshaping what comes next.
A network meta-analysis finally ranks the incretin heavyweights head-to-head, while a novel once-weekly peptide files its first big numbers. Here's what the data actually shows.
Semaglutide's clinical footprint is widening fast — new data hint at off-target wins, real-world rescues, and a sharpening list of who should pause before the pen.
Three new clinical analyses cut through the semaglutide and tirzepatide hype — quantifying real-world weight loss at one year, the muscle question lifters keep asking, and what happens when patients head into the OR.
A wave of head-to-head trials and a biased-agonist newcomer show the GLP-1 class is fragmenting into distinct molecules with measurably different profiles.
A post-hoc analysis of a randomized trial found semaglutide reduced multiple DNA-methylation aging clocks. It's early, narrow, and genuinely intriguing.